Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 NBTXR3 plus radiotherapy (± cetuximab) vs radiotherapy (± cetuximab) in elderly, platinum-ineligible locally advanced head and neck squamous cell carcinoma
jRCT2051220124Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival (PFS) based on independent central review. Started Sep 2023; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2051220124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220124.